Persistent gaps in the implementation of lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease: A French nationwide study - 02/04/25
, Thomas Goronflot b, Pierre-Guillaume Piriou a, Mathilde Pouriel c, Alexandre Bastien d, Julie Prax d, Christophe Leux e, Valéry-Pierre Riche f, Jean-Noël Trochu a, Sophie Béliard g, Nadège Costa h, Jean Ferrières i, Stéphanie Duret d, Bertrand Cariou a, ⁎ Highlights |
• | At the nationwide level, 32.5 % of French patients with established ASCVD were not receiving lipid-lowering therapy (LLT) in 2021;. |
• | Populations most at risk of not-receiving LLT are women, people under 50 or over 85 years, and those with stroke or peripheral artery disease compared to patients with coronary artery disease;. |
• | There is an urgent need for dedicated strategies for implementing recommendations in these at-risk populations as a matter of priority. |
Abstract |
Background |
According to international guidelines, lowering LDL-cholesterol is the cornerstone of atherosclerotic cardiovascular disease (ASCVD) prevention. However, observational studies have identified current gaps in the implementation of lipid-lowering therapy (LLT). This whole-population study aimed to evaluate the prevalence and determinants of LLT use in ASCVD patients.
Methods |
Using the national health data system, all French adults with established ASCVD between 2012 and 2021 were identified using specific ICD-10 and/or procedure codes. LLT use was defined as ≥1 dispensing in the last quarter of 2021. Logistic regression was used to identify factors associated with the absence of LLT use.
Findings |
In 2021, 2,206,305 individuals (4.89 % among 45,082,270 adults) had established ASCVD (mean age: 72.2 years; 36.9 % women), including 56.1 % with coronary artery disease, 40.4 % with cerebrovascular disease, and 14.5 % with revascularized peripheral artery disease (PAD). Among the 2,056,354 patients alive on 31st December 2021, 32.5 % did not receive any LLT, while 64.8 % received a statin (27.0 % a high-intensity statin), 13.0 % a combination of statin and ezetimibe, and 0.25 % a PCSK9 inhibitor. The absence of LLT use was significantly associated with female sex (adjusted odds ratio [aOR]:1.42, 95 %CI, 1.41–1.43); lowest/highest ages: < 50 years (aOR (/65–74 years): 2.23, 95 %CI 2.20–2.27) and ≥ 85 years (aOR: 2.10, 95 %CI 2.08–2.13); and stroke and PAD, compared to myocardial infarction (aOR: 2.21, 95 %CI 2.19–2.23 and 1.88, 95 %CI 1.86–1.91, respectively).
Interpretation |
In real life, one-third of French ASCVD patients was not regularly treated with LLT, highlighting the urgent need to develop implementation strategies for lipid management.
Le texte complet de cet article est disponible en PDF.Keywords : Health care information system, LDL-cholesterol, Real-word evidence, Secondary prevention, Statins, Underuse
Abbreviations : apoB, aOR, ASCVD, ATC, ATIH, CAD, CI, CKD, CVD, ESKD, GP, ICD-10, LDL-C, LLT, MACE, PAD, PCSK9i, PY, RECORD, SNDS
Plan
Vol 51 - N° 3
Article 101638- mai 2025 Retour au numéro
Article précédent
- Screening for autoimmune atrophic gastritis by serum gastrin measurement in subjects with type 1 diabetes
- Aude Pacheco, Marc Diedisheim, Claire Goulvestre, Laure Alexandre-Heymann, Roberto Mallone, Danièle Dubois-Laforgue, Etienne Larger
- Secukinumab (Anti-IL-17) induces clinical regression in early diagnosed type 1 diabetes: A case report
- Blanca Gómez-Zaragoza, María Ruiz-Rodríguez, Pablo Rodríguez de Vera Gómez, Daniela Decan-Bardasz, María Asunción Martínez-Brocca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?